Africa-Europe partnership launched to develop new AIDS vaccine

A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the ...

February 10, 2017
EATG  News  

High hepatitis C prevalence seen in Amsterdam PrEP study participants

Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline. The HCV prevalence seen was more typical of that seen in HIV-positive gay men rather than the ...

February 07, 2017
EATG  News  

Drug use and HIV: is there a correlation?

Although the use of needles to inject illegal drugs is a known risk factor in the transmission of HIV (more than 180,000 injectable drug users with HIV have died since the HIV epidemic began), less attention has been paid to general patterns of drug use ...

February 07, 2017
EATG  News  

Can a novel combination of treatments help eradicate HIV?

In first-ever study, Case School of Medicine researchers to pair monoclonal antibody with body’s own killer-cell stimulator Newswise — A Case Western Reserve University School of Medicine researcher has received a $2.5 million grant from Gilead Sciences, a California-based biopharmaceutical company, to see if two so-far ...

February 02, 2017
EATG  News  

Novel pharmaceutic action for HIV/AIDS discovered

A research team at UNMC has used a process they call LASER ART (long-acting slow effective release antiretroviral therapy) to discover an unexpected pathway to open cell storage areas for antiviral drugs. The discovery could revolutionize current treatments for HIV/AIDS by extending the actions of ...

February 02, 2017
EATG  News  

February 2017 issue of The Lancet HIV now online

The Lancet HIV is an exclusively online journal dedicated to publishing original research that advocates change in, or illuminates, HIV clinical practice. It publishes translational, epidemiological, clinical, operational, and implementation studies. The February 2017 issue is available here. Source

February 01, 2017
News  

Regulus announces continuation of RG-101 clinical hold

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for RG-101 remains on clinical hold. In ...

January 31, 2017
EATG  News  

New and touted HIV bNAb: Big deal or news blip?

Fervid research has uncovered dozens of antibodies that shield cells from HIV. These broadly neutralizing antibodies (bNAbs) protect monkeys from SHIV, the simian-HIV hybrid. Thousand-person human trials are already dripping bNAbs into high-risk men and women to see if they prevent HIV infection. And much ...

January 26, 2017
EATG  News  

Antibody combination puts HIV on the ropes

Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body’s ability to control it. But a small group of infected individuals—called elite controllers—possess immune systems capable of defeating the virus. They accomplish ...

January 26, 2017
EATG  EATG  News  News